Literature DB >> 2083666

Antibody-directed enzyme/prodrug therapy (ADEPT).

K D Bagshawe1.   

Abstract

Mesh：

Substances：

Year:  1990        PMID： 2083666     DOI： 10.1042/bst0180750

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN： 0300-5127            Impact factor:   5.407


× No keyword cloud information.
  8 in total

Review 1.  Monoclonal antibody administration. Current clinical pharmacokinetic status and future trends.

Authors:  R H Begent; R B Pedley; J Begent
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

2.  Toward antibody-directed "abzyme" prodrug therapy, ADAPT: carbamate prodrug activation by a catalytic antibody and its in vitro application to human tumor cell killing.

Authors:  P Wentworth; A Datta; D Blakey; T Boyle; L J Partridge; G M Blackburn
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-23       Impact factor: 11.205

Review 3.  The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT).

Authors:  R J Knox; F Friedlos; M P Boland
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

Review 4.  Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs).

Authors:  W A Denny; W R Wilson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

Review 5.  Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling.

Authors:  Annika Foehrenbacher; Timothy W Secomb; William R Wilson; Kevin O Hicks
Journal:  Front Oncol       Date:  2013-12-27       Impact factor: 6.244

6.  High efficiency diffusion molecular retention tumor targeting.

Authors:  Yanyan Guo; Hushan Yuan; Hoonsung Cho; Darshini Kuruppu; Kimmo Jokivarsi; Aayush Agarwal; Khalid Shah; Lee Josephson
Journal:  PLoS One       Date:  2013-03-11       Impact factor: 3.240

7.  Direct comparison of a radioiodinated intact chimeric anti-CEA MAb with its F(ab')2 fragment in nude mice bearing different human colon cancer xenografts.

Authors:  C A Vogel; A Bischof-Delaloye; J P Mach; A Pèlegrin; N Hardman; B Delaloye; F Buchegger
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

8.  A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs.

Authors:  R A Spooner; F Friedlos; K Maycroft; S M Stribbling; J Roussel; J Brueggen; B Stolz; T O'Reilly; J Wood; A Matter; R Marais; C J Springer
Journal:  Br J Cancer       Date:  2003-05-19       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.